All In Biotech

Drug Trial Radar · NCT00699374

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jan 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,075 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,075

Actual

Start

Jul 2008

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • sunitinib malateDrug

    sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.

  • sorafenibDrug

    sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150

Locations

171 sites in 23 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Fountain Valley, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    Orange, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Ringgold, Georgia

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Crestview Hills, Kentucky

  • Pfizer Investigational Site

    The Bronx, New York

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Fairfield, Ohio

  • Pfizer Investigational Site

    Hamilton, Ohio

  • Pfizer Investigational Site

    Chattanooga, Tennessee

  • Pfizer Investigational Site

    Franklin, Tennessee

  • Pfizer Investigational Site

    Gallatin, Tennessee

  • Pfizer Investigational Site

    Hermitage, Tennessee

  • Pfizer Investigational Site

    Hixson, Tennessee

  • Pfizer Investigational Site

    Lebanon, Tennessee

  • Pfizer Investigational Site

    Murfreesboro, Tennessee

  • Pfizer Investigational Site

    Nashville, Tennessee

  • Pfizer Investigational Site

    Nashville, Tennessee

  • Pfizer Investigational Site

    Nashville, Tennessee

  • Pfizer Investigational Site

    Nashville, Tennessee

  • Pfizer Investigational Site

    Smyrna, Tennessee

  • Pfizer Investigational Site

    Mechanicsville, Virginia

  • Pfizer Investigational Site

    Midlothian, Virginia

  • Pfizer Investigational Site

    Richmond, Virginia

  • Pfizer Investigational Site

    Richmond, Virginia

  • Pfizer Investigational Site

    Seattle, Washington

  • Pfizer Investigational Site

    Concord, New South Wales, Australia

  • Pfizer Investigational Site

    Elizabeth Vale, South Australia, Australia

  • Pfizer Investigational Site

    Woodville South, South Australia, Australia

  • Pfizer Investigational Site

    Melbourne, Victoria, Australia

  • Pfizer Investigational Site

    Parkville, Victoria, Australia

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.